CR11749A - Tratamiento de la disnea asociada con insuficiencia cardiaca aguda con relaxina - Google Patents

Tratamiento de la disnea asociada con insuficiencia cardiaca aguda con relaxina

Info

Publication number
CR11749A
CR11749A CR11749A CR11749A CR11749A CR 11749 A CR11749 A CR 11749A CR 11749 A CR11749 A CR 11749A CR 11749 A CR11749 A CR 11749A CR 11749 A CR11749 A CR 11749A
Authority
CR
Costa Rica
Prior art keywords
relaxin
treatment
disnea
acute cardiac
cardiac insufficiency
Prior art date
Application number
CR11749A
Other languages
English (en)
Spanish (es)
Inventor
Unemori Elaine
L Teichman Sam
Cotter Gad
R Stewart Dennis
Jo Whitehouse Martha
Original Assignee
Corthera Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corthera Inc filed Critical Corthera Inc
Publication of CR11749A publication Critical patent/CR11749A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CR11749A 2008-05-16 2010-10-22 Tratamiento de la disnea asociada con insuficiencia cardiaca aguda con relaxina CR11749A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12788908P 2008-05-16 2008-05-16
US19054508P 2008-08-28 2008-08-28
US20124008P 2008-12-08 2008-12-08
US16433309P 2009-03-27 2009-03-27

Publications (1)

Publication Number Publication Date
CR11749A true CR11749A (es) 2011-02-11

Family

ID=40834101

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11749A CR11749A (es) 2008-05-16 2010-10-22 Tratamiento de la disnea asociada con insuficiencia cardiaca aguda con relaxina

Country Status (30)

Country Link
US (7) US8053411B2 (https=)
EP (2) EP2288373B1 (https=)
JP (4) JP5651586B2 (https=)
CN (3) CN102036679A (https=)
AR (1) AR071810A1 (https=)
AU (1) AU2009246114B2 (https=)
BR (1) BRPI0913011A2 (https=)
CA (1) CA2724540C (https=)
CR (1) CR11749A (https=)
CY (1) CY1116925T1 (https=)
DK (1) DK2288373T3 (https=)
EA (2) EA201500552A1 (https=)
ES (1) ES2546287T3 (https=)
GB (2) GB2459983B (https=)
HK (1) HK1202054A1 (https=)
HR (1) HRP20150845T1 (https=)
HU (1) HUE025483T2 (https=)
IL (3) IL208992A (https=)
MA (1) MA32389B1 (https=)
MX (1) MX2010012450A (https=)
MY (2) MY159803A (https=)
NZ (3) NZ701038A (https=)
PL (1) PL2288373T3 (https=)
PT (1) PT2288373E (https=)
SG (2) SG191587A1 (https=)
SI (1) SI2288373T1 (https=)
TW (1) TWI386202B (https=)
UA (1) UA99953C2 (https=)
WO (1) WO2009140659A2 (https=)
ZA (1) ZA201007449B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011520917A (ja) * 2008-05-16 2011-07-21 コーセラ，インコーポレーテッド 慢性心不全の治療方法
CN102036679A (zh) 2008-05-16 2011-04-27 科尔泰拉公司 用松弛素治疗与急性心力衰竭相关的呼吸困难
BR112012022654A2 (pt) * 2010-03-10 2016-11-01 Univ Florida modulação de aquaporinas com relaxina
EP2601532B1 (en) * 2010-08-06 2016-01-27 Mycartis N.V. Perlecan as a biomarker for renal dysfunction
MA34521B1 (fr) 2010-08-17 2013-09-02 Ambrx Inc Polypeptides de relaxine modifiés et leurs utilisations
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
EP2726502A1 (en) * 2011-07-01 2014-05-07 Bayer Intellectual Property GmbH Relaxin fusion polypeptides and uses thereof
WO2013059879A1 (en) * 2011-10-26 2013-05-02 Howard Florey Institute Of Experimental Physiology And Medicine Compositions and methods for the treatment of fibrosis and fibrotic diseases
CN108310396B (zh) * 2012-02-14 2022-07-15 加利福尼亚大学董事会 用于心血管疾病和其它病况的旁分泌基因的全身性递送和受调节的表达
WO2013165606A1 (en) 2012-05-04 2013-11-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modulators of the relaxin receptor 1
UA117571C2 (uk) * 2012-10-26 2018-08-27 Чіесі Фармацеутічі С.П.А. Способи контролювання кров'яного тиску та зниження диспное при серцевій недостатності
MX367165B (es) 2013-04-05 2019-08-07 Scpharmaceuticals Inc Formulaciones farmacéuticas para administración subcutánea de furosemida.
US9707154B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
CA2935628A1 (en) * 2014-02-03 2015-08-06 Novartis Ag Filters for infusion sets
EP2946788A1 (en) * 2014-05-23 2015-11-25 Immundiagnostik AG Method and composition for treating heart failure with preserved ejection fraction
CN106413740A (zh) * 2014-06-13 2017-02-15 诺华股份有限公司 用于降低gdf‑15的serelaxin应用
WO2017100540A2 (en) 2015-12-09 2017-06-15 The California Institute For Biomedical Research Relaxin immunoglobulin fusion proteins and methods of use
WO2017139164A1 (en) 2016-02-12 2017-08-17 Cardiac Pacemakers, Inc. Systems and methods for patient monitoring
CN110637027B (zh) 2017-02-08 2024-08-30 百时美施贵宝公司 包含药代动力学增强子的修饰的松弛素多肽及其用途
US11832970B2 (en) 2017-07-26 2023-12-05 Cardiac Pacemakers, Inc. Worsening heart failure stratification
CN107335051A (zh) * 2017-08-18 2017-11-10 温州医科大学附属第医院 一种保护慢性心衰肾功能的药物组合物
WO2020120482A1 (en) 2018-12-10 2020-06-18 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
EP3906019B1 (en) 2019-01-04 2025-11-26 SQ Innovation AG Pharmaceutical compositions of furosemide
US12397005B2 (en) 2019-01-04 2025-08-26 Sq Innovation Ag Pharmaceutical compositions of torsemide and uses thereof
EA202192129A1 (ru) 2019-01-31 2021-10-19 ЭсСиФАРМАСЬЮТИКАЛЗ ИНК. Концентрированные жидкие фармацевтические составы фуросемида и способы их введения
AU2023332056A1 (en) 2022-08-31 2025-03-13 Relaxera Pharmazeutische Gesellschaft mbH & Co. KG Immunosuppressive medicament and method of treatment
WO2025056188A1 (en) 2023-09-15 2025-03-20 Relaxera Pharmazeutische Gmbh & Co. Kg Relaxin medication

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023321A (en) 1982-12-13 1991-06-11 Howard Florey Institute Of Experimental Physiology & Medicine Molecular cloning and characterization of a further gene sequence coding for human relaxin
US5478807A (en) 1991-08-19 1995-12-26 Genentech, Inc. Use of relaxin in the treatment of bradycardia
US5166191A (en) * 1991-08-19 1992-11-24 Genentech, Inc. Use of relaxin in cardiovascular therapy
EP0707650B1 (en) 1993-06-21 2003-05-21 Genentech, Inc. Process for producing human relaxin
CA2145515A1 (en) * 1993-07-27 1995-02-09 Mario Bigazzi Use of relaxin as therapeutic or preventing agent
US5760069A (en) 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
US5811395A (en) 1995-06-07 1998-09-22 Medical University Of South Carolina Relaxin analogs and derivatives methods and uses thereof
EP0845992B1 (en) * 1995-08-15 2002-11-20 Connetics Corporation Use of relaxin for promoting angiogenesis
WO2001058468A1 (en) * 2000-02-09 2001-08-16 Connetics Corporation Use of relaxin to treat diseases related to vasoconstriction
DE10155843A1 (de) * 2000-11-16 2003-01-30 Immundiagnostik Ag Verfahren zur Prognose und Diagnose von Herzinsuffizienz
US20050113286A1 (en) * 2002-03-18 2005-05-26 Schreiner George F. Methods for treating congestive heart failure
US7878978B2 (en) * 2004-03-18 2011-02-01 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
CN1968717B (zh) * 2004-03-30 2013-08-21 延世大学教产学协力团 含有松弛素基因的基因送递系统和使用松弛素的药物组合物
US20060264367A1 (en) 2005-05-21 2006-11-23 Howard Florey Institute Prevention of fibrosis following cardiac injury
US20080077025A1 (en) 2005-07-11 2008-03-27 Leticia Delgado-Herrera Methods for determining how to treat congestive heart failure
US8492329B2 (en) 2007-07-12 2013-07-23 Compugen Ltd. Bioactive peptides and methods of using same
JP2011520917A (ja) 2008-05-16 2011-07-21 コーセラ，インコーポレーテッド 慢性心不全の治療方法
CN102036679A (zh) * 2008-05-16 2011-04-27 科尔泰拉公司 用松弛素治疗与急性心力衰竭相关的呼吸困难

Also Published As

Publication number Publication date
WO2009140659A3 (en) 2010-07-22
IL208992A (en) 2013-09-30
AR071810A1 (es) 2010-07-14
SG10201609580YA (en) 2016-12-29
US20130116181A1 (en) 2013-05-09
HK1202054A1 (en) 2015-09-18
DK2288373T3 (en) 2015-09-28
US20120040902A1 (en) 2012-02-16
EP2829280A1 (en) 2015-01-28
EA201001771A1 (ru) 2011-06-30
MY159803A (en) 2017-02-15
JP2011520918A (ja) 2011-07-21
MX2010012450A (es) 2011-03-21
GB2459983A (en) 2009-11-18
MA32389B1 (fr) 2011-06-01
NZ589009A (en) 2012-05-25
SI2288373T1 (sl) 2015-12-31
CY1116925T1 (el) 2017-04-05
HK1151229A1 (en) 2012-01-27
CN106177914A (zh) 2016-12-07
US8415301B2 (en) 2013-04-09
EP2288373A2 (en) 2011-03-02
NZ701038A (en) 2016-01-29
US8053411B2 (en) 2011-11-08
GB2459983B (en) 2010-04-28
US20100048475A1 (en) 2010-02-25
BRPI0913011A2 (pt) 2019-09-03
IL247351A0 (en) 2016-09-29
HK1140693A1 (en) 2010-10-22
US20150320834A1 (en) 2015-11-12
EP2288373B1 (en) 2015-06-24
PT2288373E (pt) 2015-10-19
CN103212063A (zh) 2013-07-24
AU2009246114A1 (en) 2009-11-19
US9205132B2 (en) 2015-12-08
US9066916B2 (en) 2015-06-30
IL208992A0 (en) 2011-01-31
PL2288373T3 (pl) 2015-11-30
SG191587A1 (en) 2013-07-31
HK1139051A1 (en) 2010-09-10
JP5875646B2 (ja) 2016-03-02
GB2462221A (en) 2010-02-03
HK1187550A1 (zh) 2014-04-11
GB0918132D0 (en) 2009-12-02
JP2016053040A (ja) 2016-04-14
EA201500552A1 (ru) 2016-07-29
US9579363B2 (en) 2017-02-28
US20130210730A1 (en) 2013-08-15
ES2546287T3 (es) 2015-09-22
HRP20150845T1 (hr) 2015-11-06
JP5638044B2 (ja) 2014-12-10
CA2724540A1 (en) 2009-11-19
IL228244A (en) 2016-10-31
JP2015013870A (ja) 2015-01-22
GB0908432D0 (en) 2009-06-24
US20120040903A1 (en) 2012-02-16
HUE025483T2 (en) 2016-02-29
TWI386202B (zh) 2013-02-21
JP5651586B2 (ja) 2015-01-14
CN103212063B (zh) 2015-07-22
WO2009140659A2 (en) 2009-11-19
MY158327A (en) 2016-09-30
ZA201007449B (en) 2011-06-29
CA2724540C (en) 2014-07-08
GB2462221B (en) 2010-09-01
NZ598709A (en) 2013-09-27
AU2009246114B2 (en) 2013-01-31
EA022948B1 (ru) 2016-03-31
TW200948353A (en) 2009-12-01
UA99953C2 (uk) 2012-10-25
CN102036679A (zh) 2011-04-27
US8372809B2 (en) 2013-02-12
JP2013040174A (ja) 2013-02-28
US20170151311A1 (en) 2017-06-01

Similar Documents

Publication Publication Date Title
CR11749A (es) Tratamiento de la disnea asociada con insuficiencia cardiaca aguda con relaxina
MX336145B (es) Metodo para el tratamiento de insuficiencia cardiaca cronica.
ECSP10010106A (es) Trans-clomifeno para el síndrome metabólico
CL2011001529A1 (es) Uso de un modulador o agonista de los receptores s1p derivado de 2-amino-propan-1,3-diol o 2-amino-propanol para tratar una enfermedad cronica larga en un sujeto, de manera de conseguir una disminucion diaria en la frecuencia cardiaca de 2 latidos/minutos o menos; y kit que lo comprende.
PA8794401A1 (es) Acidos 6-fenilnicotinicos sustituidos y su uso
CL2011000099A1 (es) Uso de una beta-defensina humana en la manufactura de un medicamento que sirve para el tratamiento de una enfermedad intestinal inflamatoria.
ES2445846R1 (es) Una composición de combinación farmacéutica y su uso para preparar un medicamento destinado al tatamiento de la diabetes de tipo l y los trastornos metabólicos
CY1123900T1 (el) Χρηση toy fk506 για τη θεραπεια της πνευμονικης αρτηριακης υπερτασης
UY33369A (es) Heterociclilbencil-pirazoles sustituidos y su uso
AR103415A1 (es) Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2
PE20141584A1 (es) Uso de un inhibidor de aromatasa para el tratamiento del hipogonadismo y enfermedades relacionadas
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
ECSP099828A (es) Uso de ranolazina para peptido natriuretico tipo-cerebral elevado
ECSP10010464A (es) Uso de ranolazina para el tratamiento de enfermedades cardiovasculares
UY33453A (es) Método para el tratamiento de la hipertensión pulmonar mediante el uso de ranozalina
CL2009001018A1 (es) Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia, teniendo los pacientes un incremento del nivel de creatinina debido a la utilizacion de dronedarona.
UY32507A (es) Una dosis de ave5026 para el tratamiento de trombormbolismo venoso en pacientes con deterioro renal severo
CO6300936A2 (es) Procedimiento para revertir la remodelacion cardiaca electrofisiologica de un animal con cardiopatia usando beta-adrenoceptores
ES2578729T3 (es) Agente terapéutico para enfermedades relacionadas con el hígado
CU20100225A7 (es) Tratamiento de la disnea asociada con insuficiencia cardiaca aguda con relaxina
ECSP10010552A (es) Asociacion de LA dronedarona con al menos un diuretico, su aplicacion en terapeutica
AU2016219717A1 (en) Treating dyspnea associated with acute heart failure with relaxin
TN2010000504A1 (en) Treating dyspnea associated with acute heart failure with relaxin
PH12016500711A1 (en) Method of treating dyspnea associated with acute heart failure
AU2013201629B2 (en) Treating dyspnea associated with acute heart failure with relaxin